Migraine Drugs Market is Expected to Surpass at a CAGR of 3.1% Forecast by 2025
A Comprehensive research study conducted by KD Market Insights on " Migraine Drugs Market by Type (Abortive Medicine and Preventive Medicine), Route of Administration (Oral, Injection, and Others), and Distribution Channel (Hospital-based Pharmacies, Retail Pharmacies and Online Pharmacies) - Global Opportunity Analysis and Industry Forecast, 2018-2025" report offers extensive and highly detailed historical, current and future market trends in the global and regional/market. The Migraine Drugs Market report includes market size, growth drivers, barriers, opportunities, trends and other information which helps to find new opportunities in this market for the growth of the business through new technologies and developments.
Migraine is characterized by a recurrent throbbing headache, which usually lasts from four hours to three days. This occurs on one side of the head, but may spread to both sides. It is often accompanied by vomiting, sensitivity to light or sound, nausea, and disturbed vision in some cases. Migraine is sometimes preceded by an aura that is followed by fatigue. The global migraine drugs market was valued at $1,713 million in 2017, and is expected to reach $2,190 million by 2025, growing at a CAGR of 3.1% from 2018 to 2025.
Request for Sample@ https://www.kdmarketinsights.com/sample/4150
Rise in awareness among patients for migraine treatment & prevention, rapid increase in female population, and surge in prevalence of migraine drive the growth of the global migraine drugs market. However, side effects associated with migraine drugs limit the market growth. On the contrary, growth opportunities in the developing nations and emerging new therapies for migraine treatment are expected to present opportunities for the market growth during the forecast period.
The report segments the migraine drugs market based on type, route of administration, distribution channel, and region. Based on type, the market is bifurcated into abortive medicine and preventive medicine. Depending on route of administration, it is fragmented into oral, injection, and others. By distribution channel, it is categorized into hospital-based Pharmacies, retail Pharmacies, and online Pharmacies. Based on region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
KEY BENEFITS
- This report entails a detailed quantitative analysis of the overall market trends from 2017 to 2025 to identify the prevailing opportunities along with strategic assessment of the global migraine drugs market.
- Market size and estimations are based on comprehensive analysis of the applications and developments in the industry.
- An in-depth analysis based on region is provided to understand the regional market and facilitate the strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
By Type
- Abortive Medicine
- - - Triptans (Serotonin Receptor Agonists)
- - - Ergotamine Derivative
- - - Other
- Preventive Medicine
- - - Anticonvulsant
- - - Antidepressant
- - - Beta Blocker
- - - Others
By Route of Administration
- Oral
- Injection
- Others
By Distribution Channel
- Hospital-based Pharmacies
- Retail Pharmacies
- Online Pharmacies
By region
North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
The list of key players operating in this market includes:
- Abbott Laboratories
- Allergan Plc.
- AstraZeneca
- Eisai Co., Ltd.
- Endo International Plc.
- GlaxoSmithKline Plc.
- Impax Laboratories
- Johnson & Johnson
- Merck & Co.
- Pfizer Inc.
Browse Full Report with TOC @ https://www.kdmarketinsights.com/product/migraine-drugs-market-amr
Table of Contents:
CHAPTER 1: INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.3.1. List of players profiled in the report
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies, 2016-2018
3.2.3. Market share analysis, 2017
3.3. MARKET DYNAMICS
3.3.1. Drivers
3.3.1.1. Increase in prevalence of migraine
3.3.1.2. Growth in female population
3.3.1.3. Rise in awareness among patients towards migraine treatment & prevention
3.3.2. Restraints
3.3.2.1. Side effects of migraine drugs
3.3.3. Opportunities
3.3.3.1. Emerging migraine therapies
3.3.3.2. Growth opportunities in the emerging economies
3.3.4. Impact analyses
CHAPTER 4: MIGRAINE DRUGS MARKET, BY TYPE
4.1. Overview
4.2. Abortive medicines
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by type
4.2.2.1. Triptans
4.2.2.1.1. Market size and forecast
4.2.2.2. Ergotamine derivatives
4.2.2.2.1. Market size and forecast
4.2.2.3. Other abortive medicines
4.2.2.3.1. Market size and forecast
4.2.3. Market size and forecast, by region
4.2.4. Market analysis, by country
4.3. Preventive medicines
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by type
4.3.2.1. Anticonvulsants
4.3.2.1.1. Market size and forecast
4.3.2.2. Antidepressants
4.3.2.2.1. Market size and forecast
4.3.2.3. Beta blockers
4.3.2.3.1. Market size and forecast
4.3.2.4. Other preventive medicines
4.3.2.4.1. Market size and forecast
4.3.3. Market size and forecast, by region
4.3.4. Market analysis, by country
CHAPTER 5: MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Injection
5.3.1. Market size and forecast, region
5.3.2. Market analysis, by country
5.4. Other routes
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
CHAPTER 6: MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Retail pharmacies
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Hospital pharmacies
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Online pharmacies
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country
CHAPTER 7: MIGRAINE DRUGS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U.S.
7.2.2.1.1. U.S. migraine drugs market, by type
7.2.2.1.2. U.S. migraine drugs market, by route of administration
7.2.2.1.3. U.S. migraine drugs market, by distribution channel
7.2.2.2. Canada
7.2.2.2.1. Canada migraine drugs market, by type
7.2.2.2.2. Canada migraine drugs market, by route of administration
7.2.2.2.3. Canada migraine drugs market, by distribution channel
7.2.2.3. Mexico
7.2.2.3.1. Mexico migraine drugs market, by type
7.2.2.3.2. Mexico migraine drugs market, by route of administration
7.2.2.3.3. Mexico migraine drugs market, by distribution channel
7.2.3. North America migraine drugs market, by type
7.2.4. North America migraine drugs market, by route of administration
7.2.5. North America migraine drugs market, by distribution channel
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. Germany
7.3.2.1.1. Germany migraine drugs market, by type
7.3.2.1.2. Germany migraine drugs market, by route of administration
7.3.2.1.3. Germany migraine drugs market, by distribution channel
Continue…
Check for Discount @ https://www.kdmarketinsights.com/discount/4150
About Us:
KD Market Insights is one of the leading providers of market intelligence products and services. We offer reports on over 10+ industries and update our collection daily which helps our clients to access database of expert market insights on global industries, companies, products, and trends. Our in-house research experts have a wealth of knowledge in their respective domains. With KD Market Research, you always have the choice of getting customized report free of cost (up to 10%). Our support team will help you customize the report and scope as per your business needs. This ensures that you are making the right purchase decision.
Our clients list includes various Fortune 500 companies and leading advisory firms.
Contact Us:
KD Market Insights
90 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: info@kdmarketinsights.com
Website: www.kdmarketinsights.com
Read More News: https://marketresearch531064260.wordpress.com/
https://consumergoods1234.blogspot.com/
Migraine is characterized by a recurrent throbbing headache, which usually lasts from four hours to three days. This occurs on one side of the head, but may spread to both sides. It is often accompanied by vomiting, sensitivity to light or sound, nausea, and disturbed vision in some cases. Migraine is sometimes preceded by an aura that is followed by fatigue. The global migraine drugs market was valued at $1,713 million in 2017, and is expected to reach $2,190 million by 2025, growing at a CAGR of 3.1% from 2018 to 2025.
Request for Sample@ https://www.kdmarketinsights.com/sample/4150
Rise in awareness among patients for migraine treatment & prevention, rapid increase in female population, and surge in prevalence of migraine drive the growth of the global migraine drugs market. However, side effects associated with migraine drugs limit the market growth. On the contrary, growth opportunities in the developing nations and emerging new therapies for migraine treatment are expected to present opportunities for the market growth during the forecast period.
The report segments the migraine drugs market based on type, route of administration, distribution channel, and region. Based on type, the market is bifurcated into abortive medicine and preventive medicine. Depending on route of administration, it is fragmented into oral, injection, and others. By distribution channel, it is categorized into hospital-based Pharmacies, retail Pharmacies, and online Pharmacies. Based on region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
KEY BENEFITS
- This report entails a detailed quantitative analysis of the overall market trends from 2017 to 2025 to identify the prevailing opportunities along with strategic assessment of the global migraine drugs market.
- Market size and estimations are based on comprehensive analysis of the applications and developments in the industry.
- An in-depth analysis based on region is provided to understand the regional market and facilitate the strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
By Type
- Abortive Medicine
- - - Triptans (Serotonin Receptor Agonists)
- - - Ergotamine Derivative
- - - Other
- Preventive Medicine
- - - Anticonvulsant
- - - Antidepressant
- - - Beta Blocker
- - - Others
By Route of Administration
- Oral
- Injection
- Others
By Distribution Channel
- Hospital-based Pharmacies
- Retail Pharmacies
- Online Pharmacies
By region
North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
The list of key players operating in this market includes:
- Abbott Laboratories
- Allergan Plc.
- AstraZeneca
- Eisai Co., Ltd.
- Endo International Plc.
- GlaxoSmithKline Plc.
- Impax Laboratories
- Johnson & Johnson
- Merck & Co.
- Pfizer Inc.
Browse Full Report with TOC @ https://www.kdmarketinsights.com/product/migraine-drugs-market-amr
Table of Contents:
CHAPTER 1: INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.3.1. List of players profiled in the report
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies, 2016-2018
3.2.3. Market share analysis, 2017
3.3. MARKET DYNAMICS
3.3.1. Drivers
3.3.1.1. Increase in prevalence of migraine
3.3.1.2. Growth in female population
3.3.1.3. Rise in awareness among patients towards migraine treatment & prevention
3.3.2. Restraints
3.3.2.1. Side effects of migraine drugs
3.3.3. Opportunities
3.3.3.1. Emerging migraine therapies
3.3.3.2. Growth opportunities in the emerging economies
3.3.4. Impact analyses
CHAPTER 4: MIGRAINE DRUGS MARKET, BY TYPE
4.1. Overview
4.2. Abortive medicines
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by type
4.2.2.1. Triptans
4.2.2.1.1. Market size and forecast
4.2.2.2. Ergotamine derivatives
4.2.2.2.1. Market size and forecast
4.2.2.3. Other abortive medicines
4.2.2.3.1. Market size and forecast
4.2.3. Market size and forecast, by region
4.2.4. Market analysis, by country
4.3. Preventive medicines
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by type
4.3.2.1. Anticonvulsants
4.3.2.1.1. Market size and forecast
4.3.2.2. Antidepressants
4.3.2.2.1. Market size and forecast
4.3.2.3. Beta blockers
4.3.2.3.1. Market size and forecast
4.3.2.4. Other preventive medicines
4.3.2.4.1. Market size and forecast
4.3.3. Market size and forecast, by region
4.3.4. Market analysis, by country
CHAPTER 5: MIGRAINE DRUGS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Injection
5.3.1. Market size and forecast, region
5.3.2. Market analysis, by country
5.4. Other routes
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
CHAPTER 6: MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Retail pharmacies
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Hospital pharmacies
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Online pharmacies
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country
CHAPTER 7: MIGRAINE DRUGS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U.S.
7.2.2.1.1. U.S. migraine drugs market, by type
7.2.2.1.2. U.S. migraine drugs market, by route of administration
7.2.2.1.3. U.S. migraine drugs market, by distribution channel
7.2.2.2. Canada
7.2.2.2.1. Canada migraine drugs market, by type
7.2.2.2.2. Canada migraine drugs market, by route of administration
7.2.2.2.3. Canada migraine drugs market, by distribution channel
7.2.2.3. Mexico
7.2.2.3.1. Mexico migraine drugs market, by type
7.2.2.3.2. Mexico migraine drugs market, by route of administration
7.2.2.3.3. Mexico migraine drugs market, by distribution channel
7.2.3. North America migraine drugs market, by type
7.2.4. North America migraine drugs market, by route of administration
7.2.5. North America migraine drugs market, by distribution channel
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. Germany
7.3.2.1.1. Germany migraine drugs market, by type
7.3.2.1.2. Germany migraine drugs market, by route of administration
7.3.2.1.3. Germany migraine drugs market, by distribution channel
Continue…
Check for Discount @ https://www.kdmarketinsights.com/discount/4150
About Us:
KD Market Insights is one of the leading providers of market intelligence products and services. We offer reports on over 10+ industries and update our collection daily which helps our clients to access database of expert market insights on global industries, companies, products, and trends. Our in-house research experts have a wealth of knowledge in their respective domains. With KD Market Research, you always have the choice of getting customized report free of cost (up to 10%). Our support team will help you customize the report and scope as per your business needs. This ensures that you are making the right purchase decision.
Our clients list includes various Fortune 500 companies and leading advisory firms.
Contact Us:
KD Market Insights
90 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: info@kdmarketinsights.com
Website: www.kdmarketinsights.com
Read More News: https://marketresearch531064260.wordpress.com/
https://consumergoods1234.blogspot.com/
Comments
Post a Comment